Drug Name Synthroid

Ampicillin was the first of a number of so-called broad spectrum penicillins subsequently introduced by Beecham. Ampicillin is part of the aminopenicillin family and is roughly equivalent to its successor, amoxicillin in terms of spectrum and level of activity.
Doxycycline is a molecule of the cyclin family that works as an antibiotic by slowing the growth of bacteria in the body. It is a semi-synthetic tetracycline that was developed in the early 60s by Pfizer Inc. and marketed under the name Vibramycin, approved by the FDA in 1967. It was the first broad-spectrum daily antibiotic created and proved to be effective against intracellular bacteria.

 

On 23 October 2008, the European Medicines Agency (EMEA) issued a press release stating its Committee for Medical Products for Human Use (CHMP) had concluded the benefits of Acomplia no longer outweighed its risks, and subsequently recommended the product be suspended from the UK market. Sanofi-Aventis later released a press statement stating the drug had been suspended. Approval of the drug was officially withdrawn by the EMEA on 16 January 2009.
Amoxicillin (INN), formerly amoxycillin (BAN), amoxycillin (cilamox) in Australia[1], abbreviated Amox,Tormoxin (in India), is a moderate-spectrum, bacteriolytic, b-lactam antibiotic used to treat bacterial infections caused by susceptible microorganisms. It is usually the drug of choice within the class because it is better absorbed, following oral administration, than other b-lactam antibiotics. It is also a treatment for cystic acne.